Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.64 |
| ▸ | NPC1 | O15118 | 7/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.61 |
| ▸ | RELA | Q04206 | 3/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331871 | 0.88 | ADORA3 (0.58) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL27431503 | 0.86 | PTGS2 (0.66) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3613302 | 0.84 | ALDH1A1 (0.72) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3601789 | 0.84 | KDM4E (0.60) | RAB9AMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3603727 | 0.84 | GSTO1 (0.60) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL2380037 | 0.84 | RAB9A (0.61) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3597000 | 0.84 | MEN1 (0.73) | RAB9AMAPTMEN1KMT2ANPC1 | |
| SCHEMBL10922779 | 0.83 | GSTO1 (0.74) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL10814398 | 0.83 | MEN1 (0.83) | PTGS2RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3615150 | 0.83 | MEN1 (0.55) | RAB9AMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| CN-111825633-B | Method for synthesizing 2-guanidyl thiazole compounds by one-pot method | 西华大学 | 2023-11-17 | — | — | CN | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| WO-2009146013-A1 | MYOSIN LIGHT CHAIN PHOSPHATASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009146013-A1 | MYOSIN LIGHT CHAIN PHOSPHATASE INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1532963-A1 | Composition for straightening the hair comprising at least one imine not being an hydroxide | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
| EP-1532960-A1 | Hair styling composition containing a non-hydroxide imine | L'OREAL (FR) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | PTGS2 1834/4885RAB9A 1024/4885MAPT 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.